Muir-Torre Syndrome – a Phenotypic Variant of Lynch Syndrome

Česká verzia

Authors: D. Kacerovská ^1,2; D. V. Kazakov ^1,2; K. Černá ^1,2 ; L. Hadravský ¹; M. Michal Jr. ¹; J. Dostál ¹ ; A. Skálová Jr. ¹; M. Michal ^1,2
Authors place of work: Šiklův patologicko-anatomický ústav, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy, Plzeň ¹; Bioptická laboratoř s. r. o., Plzeň ²
Published in the journal: Čes.-slov. Patol., 46, 2010, No. 4, p. 86-94
Category: Přehledový článek

Summary

Muir-Torre syndrome (MTS) represents an autosomal dominantly inherited condition and is considered a phenotypic variant of the more common hereditary nonpolyposis colorectal cancer syndrome (HNPCC), or Lynch syndrome. MTS combines at least one cutaneous neoplasm with sebaceous differentiation (e.g. sebaceoma, sebaceous adenoma, and sebaceous carcinoma), and at least one visceral malignancy. MTS is a genetic disorder caused by a germline mutation in one of the DNA mismatch repair (MMR) genes. Tumors in MTS patients are characteristically associated with the loss of MMR protein expression and/or microsatellite instability (70%).

Patients who are suspected to have MTS/Lynch syndrome are often identified by dermatologists, dermatopathologists/pathologists, gastroenterologists and gynecologists. If MTS is suspected on a clinicopathological ground, necessary additional laboratory investigations should be performed only in specialized pathological departments providing immunohistochemistry and molecular biologic analysis service.

Key words:
Muir-Torre syndrome – hereditary nonpolyposis colorectal cancer – Lynch syndrome – mismatch repair (MMR) genes – MMR deficiency – MMR germline mutation – microsatellite instability

Zdroje

1. Cohen, P.R., Kohn, S.R., Kurzrock, R.: Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med., 90, 1991, s. 606–613.

2. Lynch, H.T., Fusaro, R.M., Roberts, L., Voorhees, G.J., Lynch, J.F.: Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol., 113, 1985, s. 295–301.

3. Esche, C., Kruse, R., Lamberti, C., et al.: Muir-Torre syndrome: clinical features and molecular genetic analysis. Br J Dermatol., 136, 1997, s. 913–917.

4. Graham, R., McKee, P., McGibbon, D., Heyderman, E.: Torre-Muir syndrome. An association with isolated sebaceous carcinoma. Cancer, 55, 1985, s. 2868–2873.

5. Schwartz, R.A., Torre, D.P.: The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol., 33, 1995, s. 90–104.

6. Rutten, A., Burgdorf, W., Hugel, H., et al.: Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol., 21, 1999, s. 405–413.

7. Burgdorf, W.H., Pitha, J., Fahmy, A.: Muir-Torre syndrome. Histologic spectrum of sebaceous proliferations. Am J Dermatopathol., 8, 1986, s. 202–8.

8. Greenson, J.K., Bonner, J.D., Ben-Yzhak, O., et al.: Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol., 27, 2003, s. 563–570.

9. Orta, L., Klimstra, D.S., Qin, J., et al.: Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient‘s age or other clinical characteristics. Am J Surg Pathol., 33, 2009, s. 934–944.

10. Fahmy, A., Burgdorf, W.H., Schosser, R.H., Pitha, J.: Muir-Torre syndrome: report of a case and reevaluation of the dermatopathologic features. Cancer 1982;49:1898–903.

11. Misago N, Narisawa Y.: Sebaceous neoplasms in Muir-Torre syndrome. Am J Dermatopathol., 22, 2000, s. 155–161.

12. Kazakov, D.V., Kutzner, H., Rutten, A., Mukensnabl, P., Michal, M.: Carcinoid-Like Pattern in Sebaceous Neoplasms: Another Distinctive, Previously Unrecognized Pattern in Extraocular Sebaceous Carcinoma and Sebaceoma. Am J Dermatopathol. 27, 2005, s.195–203.

13. Fukai, K., Sowa, J., Ishii, M.: Reticulated acanthoma with sebaceous differentiation. Am J Dermatopathol., 28, 2006, s.158–161.

14. Haake, D.L., Minni, J.P., Nowak, M., Abenoza, P., Nousari, C.H.: Reticulated acanthoma with sebaceous differentiation. Lack of association with Muir-Torre syndrome. Am J Dermatopathol., 31, 2009, s. 391–392.

15. Rishi, K., Font, R.L.: Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review. Ophthal Plast Reconstr Surg., 20, 2004, s. 31-36.

16. Stockl, F.A., Dolmetsch, A.M., Codere, F., Burnier, M.N., Jr.: Sebaceous carcinoma of the eyelid in an immunocompromised patient with Muir-Torre syndrome. Can J Ophthalmol., 30, 1995, s. 324–326.

17. Ackerman, A.B., Lee, S.N.: Neoplasms in all organs of Muir-Torre syndrome are carcinomas: sebaceous carcinomas and squamous-cell carcinomas (keratoacanthomas) in skin and adenocarcinomas, squamous-cell carcinomas, and transitional-cell carcinomas in internal organs. Dermatopathology: Practical & Conceptual, 5, 1999, s. 312–318.

18. Bellizzi, A.M., Frankel, W.L.: Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol., 16, 2009, s. 405–417.

19. Jass, J.R.: Role of the pathologist in the diagnosis of hereditary non-polyposis colorectal cancer. Dis Markers, 20, 2004, s. 215–224.

20. Karamurzin, Y., Rutgers, J.K.: DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol., 28, 2009, s. 239–255.

21. Garg, K., Soslow, R.A.: Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol., 62, 2009, s. 679–684.

22. Roupret, M., Yates, D.R., Comperat, E., Cussenot, O.: Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol., 54, 2008, s. 1226–1236.

23. Akhtar, S., Oza, K.K., Khan, S.A., Wright, J.: Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol., 41, 1999, s. 681–686.

24. Sparr, J.A., Bandipalliam, P., Redston, M.S., Syngal, S.: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol., 33, 2009, s. 309–312.

25. Oman, S.A., Ballinger, L., Cerilli, L.A.: Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrence. Int J Surg Pathol., 17, 2009, s. 46–50.

26. Kruse, R., Rutten, A., Lamberti, C., et al.: Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet., 63, 1998, s. 63–70.

27. Yuen, S.T., Chan, T.L., Ho, J.W., et al.: Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers. Oncogene, 21, 2002, s. 7585–7592.

28. Peltomaki, P., Lothe, R.A., Aaltonen, L.A., et al: Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res., 53, 1993, s. 5853–855.

29. Thibodeau, S.N., Bren, G., Schaid, D.: Microsatellite instability in cancer of the proximal colon. Science, 260, 1993, s. 816–819.

30. Boland, C.R., Thibodeau, S.N., Hamilton, S.R., et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58, 1998, s. 5248–5257.

31. Entius, M.M., Keller, J.J., Drillenburg, P., Kuypers, K.C., Giardiello, F.M., Offerhaus, G.J.: Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res., 6, 2000, s. 1784–9.

32. Ponti, G., Losi, L., Di Gregorio, C., et al.: Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer, 103, 2005, s. 1018–1025.

33. Mathiak, M., Rutten, A., Mangold, E., et al.: Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol., 26, 2002, s. 338–343

34. Mangold, E., Pagenstecher, C., Leister, M., et al.: A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet., 41, 2004, s. 567–572.

35. Mangold, E., Rahner, N., Friedrichs, N., et al.: MSH6 mutation in Muir-Torre syndrome: could this be a rare finding? Br J Dermatol., 156, 2007, s. 158–162.

36. Arnold, A., Payne, S., Fisher, S., et al.: An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation. Fam Cancer, 6, 2007, s. 317–321.

37. Ponti, G., Losi, L., Pedroni, M., et al.: Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol., 126, 2006, s. 2302–2307.

38. Ligtenberg, M.J., Kuiper, R.P., Chan, T.L., et al.: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’exons of TACSTD1. Nat Genet., 41, 2009, s. 112–117.

39. Barnetson, R.A., Devlin, L., Miller, J., et al.: Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. Clin Genet., 72, 2007, s. 551–555.

40. Ponti, G., Ponz de Leon, M., Maffei, S., et al.: Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clin Genet., 68, 2005, s. 442–447.

41. Shia, J., Tang, L.H., Vakiani, E., et al.: Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol., 33, 2009, s. 1639–1645.

42. Cesinaro, A.M., Ubiali, A., Sighinolfi, P., Trentini, G.P., Gentili, F., Facchetti, F.: Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol., 29, 2007, s. 351–358.

43. Morales-Burgos, A,, Sanchez, J.L., Figueroa, L.D., et al.: MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J., 27, 2008, s. 322–327.

44. Doxey, B.W., Kuwada, S.K., Burt, R.W.: Inherited polyposis syndromes: molecular mechanisms, clinicopathology, and genetic testing. Clin Gastroenterol Hepatol., 3, 2005, s. 633–641.

45. Machin, P., Catasus, L., Pons, C., et al.: Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol,., 29, 2002, s. 415–420.

46. Overbeek, L.I., Ligtenberg, M.J., Willems, R.W., et al.: Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol., 32, 2008, s. 1246–1251.

47. Chung, D.C., Rustgi, A.K.: The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med., 138, 2003, s. 560–570.

48. Domingo, E., Laiho, P., Ollikainen, M., et al.: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet., 41, 2004, s. 664–668.

49. South, C.D., Hampel, H., Comeras, I., Westman, J.A., Frankel, W.L., de la Chapelle, A.: The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst., 100, 2008, s. 277–281.

50. Plaschke, J., Engel, C., Kruger, S., et al.: Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol., 22, 2004, s. 4486–4494.

51. Singh, R.S., Grayson, W., Redston, M., et al.: Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol., 32, 2008, s. 936–942.

52. Järvinen, H.J., Renkonen-Sinisalo, L., Aktán-Collán, K., Peltomäki, P., Aaltonen, L.A., Mecklin, J.P.: Ten years after mutation testing for Lynch syndrome: cancer incidence and outcomes in mutation-positive and mutation-negative family members. J Clin Oncol., 27, 2009, s. 4793–4797.